Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.42 |
| ▸ | KLK1 | P06870 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25205458 | 0.89 | KMT2A (0.55) | KMT2AALDH1A1L3MBTL1CACNA1GCACNA1H | |
| SCHEMBL28277692 | 0.85 | KLKB1 (0.55) | KLKB1 | |
| SCHEMBL20187301 | 0.85 | ALDH1A1 (0.56) | KMT2AALDH1A1LMNAPOLBCYP19A1 | |
| SCHEMBL6052401 | 0.80 | ALDH1A1 (0.56) | KMT2AALDH1A1L3MBTL1PARP1NOTUM | |
| SCHEMBL21724299 | 0.80 | MAP3K5 (0.42) | KMT2AALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL20524627 | 0.80 | POLB (0.41) | KMT2AALDH1A1L3MBTL1LMNAPOLB | |
| SCHEMBL22712271 | 0.78 | POLB (0.40) | KMT2AALDH1A1L3MBTL1NOTUMLMNA | |
| SCHEMBL20187293 | 0.78 | KMT2A (0.43) | KMT2AALDH1A1L3MBTL1PARP1LMNA | |
| SCHEMBL19780571 | 0.78 | KLKB1 (0.47) | KMT2AALDH1A1L3MBTL1KLKB1 | |
| SCHEMBL25184413 | 0.77 | AADAT (0.47) | KMT2AALDH1A1L3MBTL1CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999715-B2 | ASK1 inhibiting agents | BIOGEN MA INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3837251-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-3837251-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| CN-113227070-A | ASK1 inhibitors | 比奥根MA公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3837251-A1 | ASK1 INHIBITING AGENTS | Biogen MA Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020036949-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036949-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | MAP3K1, MAP3K6, MAP3K10 | KMT2A 3569/4885ALDH1A1 2482/4885L3MBTL1 698/4885 |
| US-11999715-B2 | ASK1 inhibiting agents | MAP3K1, MAP3K6, MAP3K10 | KMT2A 3569/4885ALDH1A1 2482/4885L3MBTL1 698/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | KMT2A 4565/4885ALDH1A1 2787/4885L3MBTL1 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.